|
Abstract:
Chronic hepatitis B virus( HBV) infection is one of the major disease burdens worldwide. At present,the antiviral therapy for hepatitis B includes interferons and nucleos( t) ide analogues. Current therapeutic regimens based on these drugs cannot significantly increase the proportion of patients with functional cure. With a better understanding of HBV replication cycle and specific virus- host cell interactions,this article summarizes and reviews the advances in the research and development of new drugs for HBV with a focus on different action targets during the above processes.
|